KAS
ABVX

Kestra Advisory Services’s Abivax ABVX Stock Holding History

Kestra Advisory Services’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-165
Closed -$22.3K – 3122
2025
Q4 		$22.3K Buy
+165
New +$18K ﹤0.01% 4455

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Kestra Advisory Services's ABVX Position: Q1 2026 in Review

Kestra Advisory Services sold out of Abivax (ABVX) in Q1 2026, closing a stake of 165 shares — an estimated $22.3K sold.

Kestra Advisory Services first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $22.3K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Kestra Advisory Services reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 165 Abivax shares in Q1 2026, an estimated $22.3K.
  • Kestra Advisory Services first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
  • Kestra Advisory Services's Abivax position peaked at $22.3K in Q4 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.